EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data

Sameer Kassem, Buthaina Khalaila, Nili Stein, Walid Saliba, Adnan Zaina iD

Diabetes, Obesity and Metabolism · 2024-10 · 26 (10) · 4646-4652

DOI: 10.1111/dom.15828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 07.08.2024. Verfasst von Sameer Kassem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Carmel Medical Center, Haifa, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The management of type 2 diabetes mellitus has advanced in the last two decades since the introduction of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). However, multiple factors may interfere with achieving better glycaemic control. This study evaluated the differences between various GLP‐1RAs in efficacy, adherence and persistence. Materials and Methods We conducted a retrospective cohort study using the electronic medical database from Clalit Health Services. Adults with type 2 diabetes mellitus who purchased any GLP‐1RA between 2009 and 2021 were included. The Index Date was defined as the date of the first purchase of any GLP‐1RA. We evaluated the adherence, persistence and glycaemic control after GLP‐1RAs initiation. Baseline glycaemic and post‐treatment glycaemic controls were analysed.

Results

In total, 70 654 patients were included. The mean age was 11.7 ± 60.4, and 51% were females. A significant reduction in glycated haemoglobin (HbA1c) was observed in all patients who received GLP‐1RAs. However, the percentage of changes in the HbA1c was higher among weekly GLP‐1RA than daily initiators (14.6% vs. 10.2%, p < 0.001). The proportion of subjects with any decrease in HbA1c was higher among the once‐weekly compared with the daily dose (82.4% vs. 74.7%) and mainly patients initiated semaglutide or dulaglutide, with 16.0% and 14.7% reduction. The frequency of good adherence (the proportion of days covered ≥80%) was significantly higher among the weekly group odds ratio = 1.25 (95% confidence interval 1.21–1.28). Good adherence was reported in older age, female gender, Jewish ethnicity and high socio‐economic status ( p < 0.001).

Conclusions

Weekly GLP‐1RAs initiators were more adherent, persistent to therapy and achieved better glycaemic control. Epidemiological variables might play a role in achieving this goal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsDrug MonitoringAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseExenatideGlucagon-Like Peptide 1Glycated HemoglobinGlycemic ControlImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsRetrospective StudiesTreatment OutcomeSemaglutide

Stichwörter der Autor:innen

database researchglucagon‐like peptide‐1 analogueglycaemic controlreal‐world evidencetype 2 diabetes

Substanzen

Blood GlucoseExenatideGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Internal Medicine, Carmel Medical Center, Haifa, Israel.
  • Department of Internal Medicine, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.
  • Department of Clinical Pharmacology and Regulatory Management, Carmel Medical Center, Haifa, Israel.
  • Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel.
  • Department of Community Medicine and Epidemiology, Statistical Unit, Lady Davis Carmel Medical Center, Haifa, Israel.
  • Translational Epidemiology Unit and Research Authority, Lady Davis Carmel Medical Center, Haifa, Israel.

ORCID-Profile: Adnan Zaina

Zitieren

APA

Kassem, S., Khalaila, B., Stein, N., Saliba, W., & Zaina, A. (2024). Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data. Diabetes, Obesity and Metabolism, 26(10), 4646-4652. https://doi.org/10.1111/dom.15828

Vancouver

Kassem S, Khalaila B, Stein N, Saliba W, Zaina A. Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data. Diabetes, Obesity and Metabolism. 2024;26(10):4646-4652. doi:10.1111/dom.15828

BibTeX
@article{Kassem2024,
  author = {Kassem, Sameer and Khalaila, Buthaina and Stein, Nili and Saliba, Walid and Zaina, Adnan},
  title = {Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {10},
  pages = {4646--4652},
  doi = {10.1111/dom.15828}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche